KRAS and pancreatic neoplasm: Deferasirox (DFX), an iron chelator, was also found to have an antiproliferative effect on pancreatic cancer cells via the suppression of FTH1 expression, suggesting that FTH1 expression or activity may be exploited as an effective therapeutic tool to target KRAS-mutant PDAC.